| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study A Rauch, Z Kutalik, P Descombes, T Cai, J Di Iulio, T Mueller, M Bochud, ... Gastroenterology 138 (4), 1338-1345. e7, 2010 | 1473 | 2010 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 745 | 2021 |
| Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation PY Bochud, JW Chien, KA Marr, WM Leisenring, A Upton, M Janer, ... New England Journal of Medicine 359 (17), 1766-1777, 2008 | 530 | 2008 |
| Pathogenesis of sepsis: new concepts and implications for future treatment PY Bochud, T Calandra Bmj 326 (7383), 262-266, 2003 | 431 | 2003 |
| Bacteremia due to viridans streptococci in neutropenic patients: a review PY Bochud, T Calandra, P Francioli The American journal of medicine 97 (3), 256-264, 1994 | 405 | 1994 |
| Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C PY Bochud, T Cai, K Overbeck, M Bochud, JF Dufour, B Müllhaupt, ... Journal of hepatology 51 (4), 655-666, 2009 | 359 | 2009 |
| Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors PY Bochud, PH Eggiman, TH Calandra, G Van Melle, L Saghafi, ... Clinical infectious diseases 18 (1), 25-31, 1994 | 347 | 1994 |
| Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling PY Bochud, TR Hawn, A Aderem The Journal of Immunology 170 (7), 3451-3454, 2003 | 334 | 2003 |
| Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review PY Bochud, M Bonten, O Marchetti, T Calandra Critical care medicine 32 (11), S495-S512, 2004 | 306 | 2004 |
| Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C MT Dill, FHT Duong, JE Vogt, S Bibert, PY Bochud, L Terracciano, ... Gastroenterology 140 (3), 1021-1031. e10, 2011 | 295 | 2011 |
| Antibiotics in sepsis PY Bochud, MP Glauser, T Calandra Intensive Care Med 27 (Suppl 1), S33-S48, 2001 | 278 | 2001 |
| IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction S Bibert, T Roger, T Calandra, M Bochud, A Cerny, N Semmo, FHT Duong, ... Journal of Experimental Medicine 210 (6), 1109-1116, 2013 | 244 | 2013 |
| Whole-genome sequencing reveals host factors underlying critical COVID-19 A Kousathanas, E Pairo-Castineira, K Rawlik, A Stuckey, CA Odhams, ... Nature 607 (7917), 97-103, 2022 | 238 | 2022 |
| Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection PY Bochud, M Hersberger, P Taffé, M Bochud, CM Stein, SD Rodrigues, ... Aids 21 (4), 441-446, 2007 | 218 | 2007 |
| Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta‐analysis A Probst, T Dang, M Bochud, M Egger, F Negro, PY Bochud Journal of viral hepatitis 18 (11), 745-759, 2011 | 210 | 2011 |
| Community-acquired pneumonia: a prospective outpatient study PY BOCHUD, F MOSER, P ERARD, F VERDON, JP STUDER, ... Medicine 80 (2), 75-87, 2001 | 209 | 2001 |
| Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection E Patin, Z Kutalik, J Guergnon, S Bibert, B Nalpas, E Jouanguy, ... Gastroenterology 143 (5), 1244-1252. e12, 2012 | 206 | 2012 |
| IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non‐1 HCV genotypes PY Bochud, S Bibert, Z Kutalik, E Patin, J Guergnon, B Nalpas, ... Hepatology 55 (2), 384-394, 2012 | 196 | 2012 |
| Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms M Lagging, G Askarieh, F Negro, S Bibert, J Söderholm, J Westin, M Lindh, ... PloS one 6 (2), e17232, 2011 | 190 | 2011 |
| Effect of C-reactive protein–guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram … E von Dach, WC Albrich, AS Brunel, V Prendki, C Cuvelier, D Flury, ... Jama 323 (21), 2160-2169, 2020 | 186 | 2020 |
